Purchase this article with an account.
Sandra Rezar, Katharina Eibenberger, Andreas Pollreisz, Wolf Buehl, Michael Georgopoulos, Christoph Krall, Guenther Weigert, Ursula Schmidt-Erfurth, Stefan Sacu; Effect of intravitreal dexamethasone implant on intraocular cytokines and chemokines in eyes with branch and central retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2016;57(12):No Pagination Specified. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the influence of intravitreal dexamethasone implant on inflammatory and angiogenic cytokine levels in the aqueous of patients with branch and central retinal vein occlusion (BRVO/ CRVO).
In this prospective clinical trial, 40 eyes of 40 consecutive patients with macular edema (ME) due to BRVO/CRVO (25/15 patients) were treated with dexamethasone intravitreal implant (Ozurdex®) at baseline and evaluated until month 6. After 4 months re-treatment was allowed in case of recurrent ME. Aqueous humor samples were taken at baseline, month 1, month 3, month 6 and at each time of re-treatment. Concentrations of 29 different inflammatory and angiogenic cytokines were measured in the aqueous of BRVO/CRVO patients by Luminex® bead assays. A control group consisting of patients undergoing cataract surgery was included.
At baseline levels of interleukin (IL)-8, angiopoietin (ANG)-2 and intercellular adhesion molecule (ICAM)-1 were highly elevated in patients with CRVO compared to healthy controls (p=0.002; p=0.007; p=0.001). VEGF levels were significantly upregulated in both BRVO and CRVO patients (p=0.003; p=0.001). Re-treatment with dexamethasone implant was necessary after 4 months in 14/8 (BRVO/CRVO) patients, in 5/3 after 5 months and in 1 patient (BRVO) after 6 months due to recurrence of ME. Significant reduction of macrophage chemoattractant protein (MCP)-1 and IL17-E in BRVO (p<0.001; p=0.01) and MCP-1 and IL1-α concentrations in CRVO (p=0.01; p=0.003) occurred after initial dexamethasone treatment. VEGF levels did not significantly change during treatment in either group (p=0.3). A mixed effect model showed cytokine levels to be positively correlated with central retinal thickness changes.
Several inflammatory cytokines were correlated with disease activity in BRVO and CRVO patients. Intravitreal dexamethasone treatment resulted in significant alterations of the pro-inflammatory cytokines MCP-1 and IL17-E in patients with BRVO and MCP-1 and IL1-α in patients with CRVO.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only